Daniel Rooks, PhD is Project Lead of the Mobilise-D consortium and Head, Endpoint Management in Translational Medicine Discovery and Profiling at Novartis, Cambridge, MA, USA. His work focuses on developing and applying methods to reduce variability and improve data quality in clinical outcome assessments of patient function in drug development clinical trials. Prior to his current role, he led the Muscle Diseases and Neuromuscular Diseases groups in Translational Medicine and was the Early Clinical Lead of the bimagrumab program. His work with assessments in clinical trials at Novartis and before that at Harvard Medical School includes traditional pen, paper, and stopwatch and digital measures. He co-developed the SPPB Guide mobile phone app that standardizes administration and scoring of the Short Physical Performance Battery. He is a fellow of the American College of Sports Medicine.

Wim Dartee (Novartis) is Global Lead Regulatory Affairs, Devices/Sensors in Clinical Development at Novartis and has over 20 years’ experience in Regulatory Affairs and Pharmaceutical Industry. He has local (3 years NL), European, US and Global regulatory affairs experience, direct interactions with all major Regulatory agencies (EMA, key EU national health authorities, FDA, PMDA, Swissmedic), and Notified Bodies BSI, TüvSüd. He has worked across a variety of therapeutic areas, both specialized (Oncology, Tropical Medicine) as well as primary care (Respiratory, CNS and Infectious Diseases) and enjoys finding ways to optimize opportunities within the ever-changing regulatory framework.
His latest role at Novartis has focused on medical devices and combination products to prepare the organization regulatory-wise, capitalizing on opportunities in combining pharma development projects with innovative devices and digital, and with particular focus on enabling the development of digital endpoints in drug clinical development.
Wim has been the Regulatory Industry Co-Lead for the Mobilise-D Consortium since inception.

Dr. Arne Mueller, a biologist by training, obtained his PhD in Bioinformatics from the University College London, specializing in protein folding prediction. He gained industry experience through a Marie-Curie fellowship at Aventis Pharma, focusing on Toxicogenomics. Dr. Mueller's career progressed at Sanofi and Novartis, where he transitioned from pre-clinical to clinical research, with a particular focus on digital mobility endpoints.

Quantitative data scientist with experience in top-tier U.K. academia and international pharma. She received her PhD in Health Data Science from Cambridge University designing methodology in estimating diet and physical activity to predict health outcomes. She is focused on analysis and integration of data from wearables/sensors in clinical trials and is always excited to bring innovation in Drug development and post-marketing activities to support data-driven decision making.